Clinical Trials
18 trialsNCT07524257 2026-05-04
Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC
ImmunityBio, Inc.
Phase 3 Not yet recruiting
NCT07566052 2026-05-04
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Astellas Pharma Inc
Phase 3 Not yet recruiting
NCT07518147 2026-04-08
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07518173 2026-04-08
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07432178 2026-04-02
CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）
Fudan University
Phase 3 Not yet recruiting
NCT07464327 2026-03-11
A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
Hansoh BioMedical R&D Company
Phase 3 Not yet recruiting
NCT07442565 2026-03-04
SYNSTAR03
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3 Not yet recruiting
NCT07416994 2026-02-18
Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3 Not yet recruiting
NCT07371897 2026-01-28
SHINE
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT07361484 2026-01-23
Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)
BeyondSpring Pharmaceuticals Inc.
Phase 3 Not yet recruiting
NCT07333066 2026-01-12
REINFORCE
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Phase 3 Not yet recruiting
NCT07242274 2025-11-21
Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC
Jemincare
Phase 3 Not yet recruiting
NCT06996093 2025-05-30
Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor
Fudan University
Phase 3 Not yet recruiting
NCT06795503 2025-01-28
Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients
Fudan University
Phase 3 Not yet recruiting
NCT06492941 2024-07-09
A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Not yet recruiting
NCT06411171 2024-05-17
Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:
Xijing Hospital of Digestive Diseases
Phase 3 Not yet recruiting
NCT04772287 2021-02-26
Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)
Shanghai Pulmonary Hospital, Shanghai, China
Phase 3 Not yet recruiting
NCT03503136 2018-05-11
NX-NPC
Sun Yat-sen University
Phase 3 Not yet recruiting